You are here: Industry Insights > Orelabrutinib

News List

Study Result of Orelabrutinib in Patients with r/r MZL Published by American Journal of Hematology PharmaSources
September 13, 2023
American Journal of Hematology recently published the study result of BTK (Bruton Tyrosine Kinase) inhibitor orelabrutinib in patients with relapsed or refractory (r/r) Marginal Zone Lymphoma (MZL).
Latest Data of InnoCare’s Orelabrutinib Presented at the 17th International Conference on Malignant Lymphoma (ICML) PharmaSources
June 16, 2023
On June 16, 2023,InnoCare Pharma, a leading biopharmaceutical company, today announced the latest clinical data of its Bruton Tyrosine Kinase inhibitor orelabrutinib at the 17th International Conference on Malignant Lymphoma.
Data of InnoCare’s Robust Pipelines Presented at the European Hematology Association (EHA) 2023 Hybrid Congress PharmaSources
June 12, 2023
On June 12, 2023,Data of InnoCare’s robust pipelines were presented at the European Hematology Association 2023 Hybrid Congress.
Clinical Study Result of Orelabrutinib in Patients with R/R MCL Published by Blood Advances PharmaSources
May 04, 2023
Blood Advances recently published the clinical study study result of BTK inhibitor orelabrutinib in Relapsed or Refractory Mantle Cell Lymphoma patients.
InnoCare Announces Orelabrutinib Becomes the First and the Only BTK Inhibitor Approved in China for the Treatment of R/R MZL PharmaSources
April 20, 2023
April 20, 2023，InnoCare Pharma announced today that its BTK inhibitor orelabrutinib received approval from the China National Medical Products Administration in the treatment of patients with relapsed/refractory marginal zone lymphoma .
InnoCare Releases 2022 Annual Results and Business Highlights PharmaSources
March 29, 2023
28 March 2023,InnoCare Pharma, a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced 2022 annual results as of 31 December 2022.
Phase II Study of Orelabrutinib in Patients with R/R CLL/SLL Published by American Journal of Hematology PharmaSources
February 07, 2023
American Journal of Hematology recently published the phase 2 study result of BTK (Bruton Tyrosine Kinase) inhibitor orelabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) patients.
InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Orelabrutinib in Combination with Tafasitamab + Lenalidomide in China PharmaSources.com
December 20, 2022
InnoCare Pharma announced today that the Company has received approval from the Center for Drug Evaluation (CDE) to conduct a single-arm, open-label, multi-cohort phase II clinical trial.
InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Mantle Cell Lymphoma in Singapore PharmaSources.com
November 22, 2022
InnoCare Pharma that HIBRUKA (orelabrutinib) has been approved by the Health Sciences Authority (HSA) of Singapore for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (R/R MCL).
InnoCare Announces Priority Review of Orelabrutinib for the Treatment of R/R MZL by NMPA PharmaSources.com
September 06, 2022
So far, no BTK inhibitor has ever been approved for treating patients with R/R MZL in China, and hope that orelabrutinib can fill the gap in this therapeutic area.

Previous page 1 2 3 Next page